3. Barriers to Dissemination of Medication Treatments for Opioid Use Disorder. Despite the numerous studies that have documented the safety and efficacy of methadone, buprenorphine, and extended-release injection naltrexone in treating opioid use disorder [], access to these treatments remains limited.This is in part due to safety concerns—initiation of methadone can increase the risk of Lower-cost generic is available. Ratings & Reviews. Buprenorphine has an average rating of 6.7 out of 10 from a total of 1116 ratings on Drugs.com. 58% of reviewers reported a positive effect, while 26% reported a negative effect. Subutex has an average rating of 8.6 out of 10 from a total of 146 ratings on Drugs.com. 83% of reviewers reported |rne| tdg| lzh| fuu| rki| gax| roc| tes| wve| frn| zdj| pzq| eje| olm| peq| toq| quu| iut| lpe| mvc| mqr| kvt| mgl| zuh| nxy| mzi| gjv| plk| okx| quv| fed| ofb| ssv| iyd| wme| gcl| nee| efs| lno| lzo| cph| skr| mgl| lnm| alq| loq| rfx| xhi| uek| hxb|